title: Transformed follicular non-Hodgkin lymphoma.
abstract: Histologic transformation of follicular lymphoma to an aggressive non-Hodgkin lymphoma is a critical biologic event with profound implications on the natural history of this otherwise indolent disease. Recent insights into the genetic and epigenetic basis of transformation have been described, with the recognition of pivotal events governing the initiation and persistence of tumor evolution. Outcomes of patients with transformed lymphoma have historically been poor; however, several studies in the rituximab era suggest that survival may be more favorable than previously recognized. This review highlights our current understanding of transformed follicular lymphoma biology and pathogenesis, current treatment, and future directions.
authors.affiliation: Division of Hematology and Oncology and.
authors.forename: Carla
authors.initials: C
authors.lastname: Casulo
authors.affiliation: Department of Pathology, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY.
authors.forename: W Richard
authors.initials: WR
authors.lastname: Burack
authors.affiliation: Division of Hematology and Oncology and.
authors.forename: Jonathan W
authors.initials: JW
authors.lastname: Friedberg
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002051:Burkitt Lymphoma / Q000473:pathology / Q000628:therapy; D018450:Disease Progression; D044127:Epigenesis, Genetic; D006801:Humans; D008224:Lymphoma, Follicular / Q000473:pathology* / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000473:pathology* / Q000628:therapy*; D008495:Medical Oncology / Q000639:trends; D011379:Prognosis; D016499:Radioimmunotherapy; D000069283:Rituximab; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab